Business Update
Shilpa Biologics Partners with Orion Corporation to Develop and Supply Nivolumab Biosimilar for Europe
NSE
shilpamed
BSE
530549
Shilpa Biologics Private Limited, a wholly owned subsidiary of Shilpa Medicare Limited, has entered into a strategic co-development and supply agreement with Finland-based Orion Corporation for an intravenous (IV) nivolumab biosimilar targeting the European market. Under the agreement, Orion will hold exclusive commercialization rights in Europe, while Shilpa will lead development, manufacturing and long-term commercial supply from its biologics facility in Dharwad, India.
PRICE-SENSITIVE TRIGGER
Event: Shilpa Biologics entered into a co-development and supply agreement with Orion Corporation for a nivolumab biosimilar.
Type: Business Update
Impact: Positive
Immediate Effect: The agreement expands Shilpa’s biologics partnership with Orion into immuno-oncology, providing long-term manufacturing opportunities, milestone payments and future supply revenues while strengthening its presence in the European biosimilars market.
Key Metrics:
- Target Market Size (Europe Nivolumab Market): Approximately USD 4.1 billion (2025)
- Development Milestone Payments:Â Undisclosed
- Long-term Supply Revenue:Â Applicable (value not disclosed)
- Agreement Consideration:Â Confidential
- Revenue:Â Not disclosed
- EBITDA:Â Not disclosed
- PAT:Â Not disclosed
- Margins:Â Not disclosed
- QoQ / YoY Movement:Â Not disclosed
- Segment Performance:Â Not disclosed
Highlight:
- The collaboration targets Europe’s approximately USD 4.1 billion nivolumab market, positioning Shilpa as the exclusive long-term manufacturing partner for the region.
What Happened ?
Shilpa Biologics Private Limited (SBPL), a wholly owned subsidiary of Shilpa Medicare Limited, has entered into a co-development and supply agreement with Orion Corporation, Finland, for an intravenous (IV) nivolumab biosimilar.
Under the collaboration, Orion will obtain exclusive rights to register, market, distribute and commercialize the biosimilar across Europe, while Shilpa Biologics will undertake product development and serve as the exclusive long-term commercial manufacturer and supplier from its EU-GMP-certified biologics facility in Dharwad, India.
The partnership builds upon the companies’ earlier collaboration involving Recombinant Human Albumin and expands their relationship into the rapidly growing immuno-oncology segment.
Key Details
Agreement Highlights:
- Shilpa Biologics has partnered with Orion Corporation, Finland.
- The collaboration covers an intravenous (IV) nivolumab biosimilar for the European market.
- Orion receives exclusive rights to register, market, distribute and sell the product across Europe.
- Orion will act as the Marketing Authorisation Holder for the territory.
- Shilpa will lead product development and remain the exclusive long-term commercial manufacturer and supplier.
- Manufacturing will be undertaken from Shilpa’s advanced biologics facility in Dharwad, India.
- Shilpa will receive development and regulatory milestone payments in addition to long-term product supply revenue.
- Financial consideration for the agreement remains confidential.
- The collaboration aims to improve access to affordable immuno-oncology therapies following the loss of exclusivity of the reference product.
- The agreement combines Shilpa’s biologics manufacturing capabilities with Orion’s commercial, regulatory and distribution expertise across Europe.
Note:
- The agreement represents another strategic milestone in the long-standing partnership between Shilpa and Orion and expands the collaboration into one of the largest global oncology biosimilar opportunities.
Risk Analysis
Summary:
- Although the partnership strengthens Shilpa’s biologics pipeline, commercial success depends on product development, regulatory approvals, successful clinical execution, manufacturing timelines and market adoption across Europe.
Key Risks:
- Biosimilar development remains subject to regulatory approvals.
- Clinical development timelines may impact commercialization.
- Commercial success depends on physician and payer adoption.
- Competition from other biosimilar manufacturers may affect market share.
- Milestone payments and supply revenues are contingent upon successful development and commercialization.
Worst Case:
- Regulatory delays or unsuccessful development could postpone commercialization, delaying milestone payments and long-term manufacturing revenues.
Risk Level: Medium
Company Commentary
- Management stated that the partnership extends the successful relationship with Orion into immuno-oncology.
- Shilpa believes the agreement reflects global partners’ confidence in its biologics development and manufacturing capabilities.
- The company expects the collaboration to improve global access to affordable advanced biologic medicines.
- Orion stated that the agreement supports its strategy of strengthening its hospital business across Continental Europe.
- Both companies highlighted that the partnership combines Shilpa’s manufacturing expertise with Orion’s regulatory and commercial capabilities to broaden patient access to oncology treatments.
Official Exchange Filing: Shilpa Medicare Limited
